arrow Log In to View Account     |      
HOME
Johns Hopkins Medicine
Hopkins Logo



Click below to register.

Sunday, October 28, 2018
Marriott Marquis Chicago

2121 S Prairie Ave
Chicago, IL
Room: Grand Horizon E/F – Level 4

6:00 AM – 6:30 AM: Registration and Breakfast
6:30 AM – 8:00 AM: Interactive Educational Activity

OVERVIEW
Despite the critical role of vascular endothelial growth factor (VEGF) inhibitors in managing patients with diabetic macular edema (DME), up to half of patients fail to respond or experience inadequate response to first-line monotherapy with these agents and remain at high risk for vision loss due to persistent edema. Increasing evidence has demonstrated the significance of inflammation, in addition to angiogenesis, as part of the underlying pathogenesis of DME. Steroids and steroid implants, which provide sustained anti-inflammatory activity, offer an efficacious treatment option for these patients, particularly for those who are refractory to anti-VEGF therapies and who experience chronic DME. In order to develop and provide individualized, efficacious treatment plans for patients with DME, considering both anti-VEGF agents and steroids, ophthalmology healthcare providers (HCPs) require the most up-to-date clinical information to inform treatment decision-making.

GOAL
The goal of this activity is to provide ophthalmology HCPs with comprehensive education that will inform DME treatment decision-making, including the rationale for and mechanism of anti-inflammatory treatments for DME, strategies to identify patients who are likely to benefit from such treatment options, as well as strategies to develop, implement, manage individualized treatment paradigms.

INTENDED AUDIENCE
This activity is designed to meet the educational needs of retina specialists and comprehensive ophthalmologists. No prerequisites required.

LEARNING OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:
  • DESCRIBE the inflammatory mechanisms that contribute to DME pathology & serve as a target for treatment.
  • EVALUATE the efficacy, safety & clinical utility of steroids as part of treatment paradigms for DME.
  • RECOGNIZE the importance of resolving residual macular edema on attaining gains in visual acuity.
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this activity.

PARTICIPATING FACULTY
J. Fernando Arevalo, MD, FACS (Chair)
Edmund F. and Virginia B. Ball Professor of Ophthalmology
Johns Hopkins Wilmer Eye Institute
Baltimore, Maryland

Peter A. Campochiaro, MD
Eccles Professor of Ophthalmology and Neuroscience
The Wilmer Eye Institute
Johns Hopkins University School of Medicine
Baltimore, MD

Andrew A. Moshfeghi, MD, MBA
Director, Clinical Trials Unit and Retina Fellowship
Associate Professor, Ophthalmology
USC Roski Eye Institute, Retina Service
Keck School of Medicine
University of Southern California
Los Angeles, California

FEE INFORMATION
There is no fee for this educational activity.


<img src="http://asimmedia.com/sites/jhasio/webcasts/pictures/proceedToPre.png" alt="procced to pretest" border="0" />
footer